BioSpace News Archive

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 2,250 ordinary shares of Nabriva Therapeutics as an inducement to a newly-hired employee.

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees restricted stock units to acquire 44,500 shares of the company’s common stock.

Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, August 11, 2021.

via NewMediaWire – Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, has been invited to present at the Access to Giving Virtual Investor conference, which is being held July 13-15.

Pharvaris announced the presentation of clinical data supporting the multiple-dose safety and pharmacokinetic profile of PHA121 for the treatment of hereditary angioedema at the European Academy of Allergy and Clinical Immunology Annual Congress 2021, being held virtually from July 10-16, 2021.

The ultrasound transducer market is expected to reach US$ 5,020.76 million in 2027 from US$ 3,816.25 million in 2019; it is estimated to grow at a CAGR of 3.6% from 2020-2027.

CerraCap Ventures, a leading early-stage Venture Fund, announced acquisition of its portfolio company Totient by Absci for an undisclosed amount.

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced positive results from its full phase 1 clinical trial for MORF-057, an oral small molecule inhibitor of the α4β7 integrin in development for the treatment of inflammatory bowel disease.

Humanigen, Inc., announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in June 2021, has been accepted by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.

Avisa Diagnostics Inc., a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, announced that the Company will participate in several virtual investor events in July.